Advances in nanoprobes for molecular MRI of Alzheimer's disease

Authors:

Abstract
Alzheimer's disease is the most common cause of dementia and a leading cause of mortality in the elderly population. Diagnosis of Alzheimer's disease has traditionally relied on evaluation of clinical symptoms for cognitive impairment with a definitive diagnosis requiring post‐mortem demonstration of neuropathology. However, advances in disease pathogenesis have revealed that patients exhibit Alzheimer's disease pathology several decades before the manifestation of clinical symptoms. Magnetic resonance imaging (MRI) plays an important role in the management of patients with Alzheimer's disease. The clinical availability of molecular MRI (mMRI) contrast agents can revolutionize the diagnosis of Alzheimer's disease. In this article, we review advances in nanoparticle contrast agents, also referred to as nanoprobes, for mMRI of Alzheimer's disease.This article is categorized under: Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Neurological Disease
Funding Information
  • Fondation Leducq (22CVD03)
  • National Institutes of Health (R01CA159042, R01HD094347, R01HL159988, R33HD105593, R61HD105593, RF1AG070149, U01DE028233)
  • American Heart Association (19CSLOI34660145)
  • Gillson Longenbaugh Foundation

This publication has 165 references indexed in Scilit: